CAPR Capricor Therapeutics Inc
P/E
--
Forward P/E
78.74
Price/Sales
124.43
Beta
0.528
Div Yield
--
Market Cap
--
Company Analysis
Latest News
Capricor's One Drug, No Revenue, and a Ticking Clock — Can a Regulatory Pivot Save a Company Running Out of Time?
Shares of Capricor Therapeutics tumbled 8.9% to $6.78 on August 18 as investors weighed a cascade of bad news: a widening quarterly loss, a damaging FDA...
🔴 Capricor Therapeutics is trading 8.93% down today after FDA panel votes against deramiocel’s effectiveness
Capricor Therapeutics is trading 8.93% down at $6.78 after an FDA advisory panel voted 9-3 against deramiocel’s effectiveness for Duchenne muscular dystrophy...
🟢 Capricor Therapeutics is trading 6.1% up today after amended Deramiocel BLA strategy and Cantor upgrade
Capricor Therapeutics is trading 6.09% up now at $7.05, extending the August 14 rally after management outlined an amended Deramiocel BLA strategy focused on...